Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP975586.RA4LuC0oUl68E_clATeCZW73JV6o_YTxOK5s7P-NaJ0dI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP975586.RA4LuC0oUl68E_clATeCZW73JV6o_YTxOK5s7P-NaJ0dI130_assertion type Assertion NP975586.RA4LuC0oUl68E_clATeCZW73JV6o_YTxOK5s7P-NaJ0dI130_head.
- NP975586.RA4LuC0oUl68E_clATeCZW73JV6o_YTxOK5s7P-NaJ0dI130_assertion description "[BRAF mutation was mainly detected in SSA/P with dysplasia (95%), SSA/P (85%), microvesicular HP (76%), and traditional serrated adenoma (54%), whereas KRAS mutation was present mainly in goblet cell HP (50%) and in tubulovillous adenoma (45%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP975586.RA4LuC0oUl68E_clATeCZW73JV6o_YTxOK5s7P-NaJ0dI130_provenance.
- NP975586.RA4LuC0oUl68E_clATeCZW73JV6o_YTxOK5s7P-NaJ0dI130_assertion evidence source_evidence_literature NP975586.RA4LuC0oUl68E_clATeCZW73JV6o_YTxOK5s7P-NaJ0dI130_provenance.
- NP975586.RA4LuC0oUl68E_clATeCZW73JV6o_YTxOK5s7P-NaJ0dI130_assertion SIO_000772 22510757 NP975586.RA4LuC0oUl68E_clATeCZW73JV6o_YTxOK5s7P-NaJ0dI130_provenance.
- NP975586.RA4LuC0oUl68E_clATeCZW73JV6o_YTxOK5s7P-NaJ0dI130_assertion wasDerivedFrom befree-2016 NP975586.RA4LuC0oUl68E_clATeCZW73JV6o_YTxOK5s7P-NaJ0dI130_provenance.
- NP975586.RA4LuC0oUl68E_clATeCZW73JV6o_YTxOK5s7P-NaJ0dI130_assertion wasGeneratedBy ECO_0000203 NP975586.RA4LuC0oUl68E_clATeCZW73JV6o_YTxOK5s7P-NaJ0dI130_provenance.